Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-UMIN000022622
JPRN-UMIN000022622Completed未知

A study to elucidate the effect of application conditions of a percutaneously absorbed type beta-1 blocker in healthy adults

Toa Eiyo Ltd.0 sites12 target enrollmentStarted: June 6, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
12
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 35years-old (—)
Sex
Male

Inclusion Criteria

  • •1,Healthy male Japanese aged from 20 to 35 years old (at acquisition time of informed consent).
  • •2,The person whose BMI [weight [kg]/(height [m])2] is 18.5 or more but less than 25.0 (cut off at 2 decimal places).
  • •3,The person who is judged to be eligible as the study subjects for this study by a principal investigator or an investigator in charge of this study by taking into account the backgrounds of volunteers obtained in screening tests (medical history, allergy, favorite food and drinks, etc.), physical findings, results of physiological test, clinical examination values, etc.

Exclusion Criteria

  • •1.Having disease to be cured now
  • •2.Having drug/cutaneous allergy or its PH
  • •3.Having disease affecting drug ADME in GIT, heart, liver, & kidney, or its PH
  • •4.Having allergic diseases like asthma, pollen disease now
  • •5.SBP is <90 mmHg or pulse rate <55/min at screening
  • •6.Having PH of skin rash by external drugs 7.Having cutaneous diseases (e.g., dermatitis, pigment deposition, external injury) preventing from assessing effect at dose site
  • •8.Having skin hair preventing from securing dose site, having tattoo/birthmark at the site, or often making sunburn his skin
  • •9.Giving 400 mL oe more of WB within 12 W before dosing, giving 200 mL or more of WB or having such a plan within 4 W before dosing, or giving blood components or having such a plan within 2 W before dosing
  • •10.Using a drug except said test drug or having such a plan within 1 W before dosing (except artificial tears)
  • •11.Participating in another study and receiving a study drug or having such a plan within 16 W before dosing (within 4 W in a patch test)
  • •12.Positive to any of immunological test item/deviating from its standard laboratory values at screening
  • •13.Judged as undesirable as subject by principal investigator or investigator charged

Investigators

Similar Trials

Not yet recruiting
Not Applicable
An Investigation of the effect of using a conformable and wearable ice pack on pain and discomfort following sacroiliac joint injection.Mechanical Sacroiliac joint dysfunctionMusculoskeletal - Other muscular and skeletal disorders
ACTRN12622000554763niveristy of Notre Dame Australia80
Not yet recruiting
Phase 2
Prospective study to explore the impact of the continuous individual nutritional counseling on the body weight loss in post-gastrectomy patientsGastric cancer
JPRN-UMIN000033548ara Medical University, Department of Surgery60
Recruiting
Phase 4
Treatment of Comorbid Depression and Substance Abuse in Young PeopleComorbidity of depression and substance use issuesMental Health - Depression
ACTRN12605000675628Melbourne Health50
Recruiting
Phase 2
A prospective study to investigate the effect of CBM558 combined with pembrolizumab on gut microbiota and prognosis in patients with advanced urothelial carcinoma.
JPRN-jRCTs031220689Taguchi Satoru30
Not yet recruiting
Unknown
A cross-sectional survey on herb-drug interaction between Giloy and conventional medications along with its in vitro estimation by cytochrome P-450 enzymes
CTRI/2023/05/052854All India Institute of Ayurveda
A study to elucidate the effect of ... | Clinical Trial